Not Yet RecruitingNot Applicable

Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas

France22 participantsStarted 2025-06-30

Plain-language summary

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024 Exclusion Criteria: * Individuals who have objected to the use of their data

What they're measuring

Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy

Timeframe: one day

Trial details

NCT IDNCT07017790

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-01

Contact for this trial

Antoine VERGER, MD,PhD

0383155567 a.verger@chru-nancy.fr

View on ClinicalTrials.gov More Glioma trials